An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single-dose, Crossover Bioequivalence Study Comparing Pantoprazole Sodium 40 mg Delayed Release Tablets (Containing 45.1 mg of Pantoprazole Sodium Sesquihydrate Equivalent to 40 mg of Pantoprazole) of Ohm Laboratories Inc. (a Subsidiary of Ranbaxy Pharmaceuticals Inc, USA) With PROTONIX 40 mg Delayed Release Tablets (Containing 45.1 mg of Pantoprazole Sodium Sesquihydrate Equivalent to 40 mg of Pantoprazole) of Wyeth Pharmaceuticals Inc. in Healthy, Adult, Male, Human Subjects Under Fasting Conditions.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Pantoprazole (Primary)
- Indications Gastro-oesophageal reflux; Heartburn; Helicobacter infections; Peptic ulcer
- Focus Pharmacokinetics
Most Recent Events
- 10 Aug 2012 New trial record
- 01 Aug 2012 Biomarkers information updated